I consider the psychedelic churches/groups to be part of the underground. Free from the restrictions that will be placed on the clinics. No hyper concerns of insurance reimbursement but still needing to pay attention to harm reduction and ethical issues.
Sharp synthesis, and calling the 6-to-8 hour session the constraint everything else runs through is the right framing; the Oregon closure rate makes it concrete in a way the deal headlines don't.
The variable I'd watch next to your faster-acting and group-dosing levers is durability, how often people actually need to come back, since that drives lifetime cost more than per-session overhead does. Your own Spravato figure hints at it: 584 million and climbing looks a lot more like repeat dosing than one-and-done.
We are in the early "formulation" stages of psychedelics as recognized clinical applications. The Portland Psychedelic Society deserves credit for its years of working with legislators to pass legislation, build a structure, and certify practitioners. As we are in the early stages of formulation, we try, test, and adjust or redesign models for effectiveness, efficiency, and cost. It will take some time to figure it out, but the point is it's out the door, down the road, and on its way.
Any thoughts on the part that might be played by organizations like mine – entheogenic churches?
I consider the psychedelic churches/groups to be part of the underground. Free from the restrictions that will be placed on the clinics. No hyper concerns of insurance reimbursement but still needing to pay attention to harm reduction and ethical issues.
Thank you so much for that clarification. I totally agree - especially with the harm reduction piece!
Sharp synthesis, and calling the 6-to-8 hour session the constraint everything else runs through is the right framing; the Oregon closure rate makes it concrete in a way the deal headlines don't.
The variable I'd watch next to your faster-acting and group-dosing levers is durability, how often people actually need to come back, since that drives lifetime cost more than per-session overhead does. Your own Spravato figure hints at it: 584 million and climbing looks a lot more like repeat dosing than one-and-done.
You are right about durability. That will affect the process and potential.
Clinical reckoning precedes industrial capture
We are in the early "formulation" stages of psychedelics as recognized clinical applications. The Portland Psychedelic Society deserves credit for its years of working with legislators to pass legislation, build a structure, and certify practitioners. As we are in the early stages of formulation, we try, test, and adjust or redesign models for effectiveness, efficiency, and cost. It will take some time to figure it out, but the point is it's out the door, down the road, and on its way.